drop glp 1 the wellness company GLP-1 therapies are changing obesity care. What does WHO recommend? , Here’s what you need to know FDA is moving to restrict

More serious potential adverse effects include pancreatitis, gallbladder disease (cholelithiasis, cholecystitis), acute kidney injury (especially with dehydration), and increased risk of hypoglycemia when used with insulin or sulfonylureas

Janoshik testing defends against this by confirming identity via mass spectrometry

Hashash JG, Thompson CC, Wang AY

Beyond their effects on insulin secretion, GLP-1 agonists suppress glucagon release from pancreatic alpha cells, slow gastric emptying, and promote satiety through central nervous system pathways

[18] [19] At the higher doses used for weight management, headache rates can exceed 10%

However, it's crucial to consult your doctor before taking any medications to ensure they won't interact with your Semaglutide treatment